BACKGROUND AND OBJECTIVES: Omission of routine axillary staging and adjuvant radiation (XRT) in women ≥ 70 years old with early stage, hormone receptor-positive, clinically node-negative breast cancer has been endorsed based on several landmark studies. We sought to determine how much omission of axillary staging/XRT has been adopted. METHODS: Using the National Cancer Data Base, we selected malignant breast cancer cases in women ≥ 70 with ER + tumors, ≤2 cm with clinically negative lymph nodes who underwent breast conservation and had known XRT status in 2005-2015. The use of sentinel lymph node biopsy (SNB) and XRT status was summarized by year to determine trends over time. RESULTS: In total, 57 230/69 982 patients underwent SNB. Of the 12 752 patients in whom SNB was omitted, 6296 were treated at comprehensive community cancer programs. Regarding XRT, 33 891/70 114 received adjuvant XRT. There were no significant trends with regards to patients receiving SNB or those receiving XRT. CONCLUSION: Since 2005, there has been no change in SNB or XRT for early stage ER + breast tumors. However, there was a difference in omission of SNB based on facility type and setting. Future monitoring is needed to determine if these trends persist following the recently released Choosing Wisely® recommendations.
BACKGROUND AND OBJECTIVES: Omission of routine axillary staging and adjuvant radiation (XRT) in women ≥ 70 years old with early stage, hormone receptor-positive, clinically node-negative breast cancer has been endorsed based on several landmark studies. We sought to determine how much omission of axillary staging/XRT has been adopted. METHODS: Using the National Cancer Data Base, we selected malignant breast cancer cases in women ≥ 70 with ER + tumors, ≤2 cm with clinically negative lymph nodes who underwent breast conservation and had known XRT status in 2005-2015. The use of sentinel lymph node biopsy (SNB) and XRT status was summarized by year to determine trends over time. RESULTS: In total, 57 230/69 982 patients underwent SNB. Of the 12 752 patients in whom SNB was omitted, 6296 were treated at comprehensive community cancer programs. Regarding XRT, 33 891/70 114 received adjuvant XRT. There were no significant trends with regards to patients receiving SNB or those receiving XRT. CONCLUSION: Since 2005, there has been no change in SNB or XRT for early stage ER + breast tumors. However, there was a difference in omission of SNB based on facility type and setting. Future monitoring is needed to determine if these trends persist following the recently released Choosing Wisely® recommendations.
Authors: Ian H Kunkler; Linda J Williams; Wilma J L Jack; David A Cameron; J Michael Dixon Journal: Lancet Oncol Date: 2015-01-28 Impact factor: 41.316
Authors: Viviana Galimberti; Bernard F Cole; Giuseppe Viale; Paolo Veronesi; Elisa Vicini; Mattia Intra; Giovanni Mazzarol; Samuele Massarut; Janez Zgajnar; Mario Taffurelli; David Littlejohn; Michael Knauer; Carlo Tondini; Angelo Di Leo; Marco Colleoni; Meredith M Regan; Alan S Coates; Richard D Gelber; Aron Goldhirsch Journal: Lancet Oncol Date: 2018-09-05 Impact factor: 41.316
Authors: Andrew M Heekin; John Kontor; Harry C Sax; Michelle S Keller; Anne Wellington; Scott Weingarten Journal: Am J Manag Care Date: 2018-08 Impact factor: 2.229
Authors: Jayant S Vaidya; David J Joseph; Jeffrey S Tobias; Max Bulsara; Frederik Wenz; Christobel Saunders; Michael Alvarado; Henrik L Flyger; Samuele Massarut; Wolfgang Eiermann; Mohammed Keshtgar; John Dewar; Uta Kraus-Tiefenbacher; Marc Sütterlin; Laura Esserman; Helle M R Holtveg; Mario Roncadin; Steffi Pigorsch; Marinos Metaxas; Mary Falzon; April Matthews; Tammy Corica; Norman R Williams; Michael Baum Journal: Lancet Date: 2010-07-10 Impact factor: 79.321
Authors: Bernard Fisher; John Bryant; James J Dignam; D Lawrence Wickerham; Eleftherios P Mamounas; Edwin R Fisher; Richard G Margolese; Lois Nesbitt; Soonmyung Paik; Thomas M Pisansky; Norman Wolmark Journal: J Clin Oncol Date: 2002-10-15 Impact factor: 44.544
Authors: Benjamin D Smith; Soren M Bentzen; Candace R Correa; Carol A Hahn; Patricia H Hardenbergh; Geoffrey S Ibbott; Beryl McCormick; Julie R McQueen; Lori J Pierce; Simon N Powell; Abram Recht; Alphonse G Taghian; Frank A Vicini; Julia R White; Bruce G Haffty Journal: Int J Radiat Oncol Biol Phys Date: 2010-07-16 Impact factor: 7.038
Authors: Anthony W Fyles; David R McCready; Lee A Manchul; Maureen E Trudeau; Patricia Merante; Melania Pintilie; Lorna M Weir; Ivo A Olivotto Journal: N Engl J Med Date: 2004-09-02 Impact factor: 91.245
Authors: Kevin S Hughes; Lauren A Schnaper; Jennifer R Bellon; Constance T Cirrincione; Donald A Berry; Beryl McCormick; Hyman B Muss; Barbara L Smith; Clifford A Hudis; Eric P Winer; William C Wood Journal: J Clin Oncol Date: 2013-05-20 Impact factor: 44.544
Authors: Vratislav Strnad; Oliver J Ott; Guido Hildebrandt; Daniela Kauer-Dorner; Hellen Knauerhase; Tibor Major; Jaroslaw Lyczek; Jose Luis Guinot; Jürgen Dunst; Cristina Gutierrez Miguelez; Pavel Slampa; Michael Allgäuer; Kristina Lössl; Bülent Polat; György Kovács; Arnt-René Fischedick; Thomas G Wendt; Rainer Fietkau; Marion Hindemith; Alexandra Resch; Anna Kulik; Leo Arribas; Peter Niehoff; Fernando Guedea; Annika Schlamann; Richard Pötter; Christine Gall; Martina Malzer; Wolfgang Uter; Csaba Polgár Journal: Lancet Date: 2015-10-19 Impact factor: 79.321
Authors: Hely Shah; Julian Surujballi; Arif Ali Awan; Brian Hutton; Angel Arnaout; Risa Shorr; Lisa Vandermeer; Mashari Jemaan Alzahrani; Mark Clemons Journal: Breast Cancer Res Treat Date: 2020-11-06 Impact factor: 4.872
Authors: Annie Tang; Caitlin M Cohan; Genna Beattie; Elizabeth L Cureton; Jonathan D Svahn; Liisa L Lyon; Jason F Kelly; Veronica C Shim Journal: Ann Surg Oncol Date: 2021-03-09 Impact factor: 5.344